Catalyst Crew Technologies Corp. (OTC: CCTC), a digital health and artificial intelligence technology company, announced the development of PulmoAI, an AI-enabled module designed to support the detection and predictive analysis of pulmonary diseases. The platform is intended to assist healthcare providers in analyzing respiratory health data and identifying potential clinical risks through artificial intelligence-driven analytics.
PulmoAI's proposed capabilities include automated interpretation of thoracic imaging, detection of pulmonary abnormalities, and predictive modeling of disease progression. The platform integrates multiple data inputs, including CT scans, chest X-rays, pulmonary function tests, and inflammatory biomarkers, to generate structured outputs for clinical review and care coordination.
PulmoAI is part of Catalyst Crew's broader AI healthcare platform and is expected to function as a specialized module within its digital health ecosystem. Management believes modular AI systems can support scalable deployment across telehealth services, remote diagnostics, and technology-enabled healthcare delivery environments. The company intends to integrate PulmoAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform, to support early detection and data-driven insights across multiple points of care.
Catalyst Crew Technologies prioritizes market development in Latin America, where AI-enabled healthcare technologies may help expand access to respiratory diagnostics, support earlier identification of pulmonary conditions, and improve healthcare system efficiency. Dr. Kevin Rodan Levy, CEO, stated: “Artificial intelligence has the potential to enhance how healthcare providers detect and monitor pulmonary conditions, particularly in environments where access to specialized diagnostics may be limited. PulmoAI reflects our commitment to building scalable, technology-driven solutions to support healthcare delivery.”
The company intends to continue developing and refining PulmoAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment. For more information, visit https://catalystcrewai.com or review the company’s SEC filings at www.sec.gov.
